Key result
Takotsubo syndrome is linked to a lower risk of adverse events compared to heart failure.
Why the study?
Long-term outcomes of patients with Takotsubo syndrome compared to heart failure were not well characterized.
Does Takotsubo syndrome have a different long-term prognosis compared to heart failure in adult patients?
Observational (n=267,804)
Yes
Does Takotsubo syndrome have a different long-term prognosis compared to heart failure in adult patients?
Hazard Ratio: 0.622 (95% CI 0.539–0.717)
Takotsubo syndrome is associated with a lower long-term risk of adverse cardiovascular events, including acute heart failure and arrhythmias, compared to typical heart failure.
Supports distinct TTS-HF risk stratification in counseling and follow-up; extends prior evidence with global federated data.
INTRODUCTION: To compare long-term outcomes of patients with Takotsubo syndrome (TTS) and heart failure (HF). METHODS: This retrospective observational study used the TriNetX global federated research network. Adult patients (≥18 years) discharged with a diagnosis of TTS (ICD-10-CM I51.81) or HF (I50.x) between 2018 and 2022 were identified. Primary outcomes were 3-year risk of all-cause death, major adverse cardiovascular events (MACE; myocardial infarction or ischaemic stroke), and acute HF. Secondary outcomes included myocardial infarction, ischaemic stroke, ventricular arrhythmias (ventricular tachycardia), malignant arrhythmias (ventricular fibrillation or cardiac arrest), and new-onset atrial fibrillation (AF). Cox proportional hazards models estimated hazard ratios (HRs) with 95% confidence intervals (CIs) before and after 1:1 propensity score matching (PSM). Subgroup analyses were performed by HF phenotype, age (≥65 vs <65 years), and mental health status. RESULTS: The study included 2240 patients with TTS (mean age 62.6 ± 17.3 years; 73.7% female) and 265 564 patients with HF (69.3 ± 14.7 years; 45.8% female). After PSM, TTS was associated with a lower risk of acute HF (HR 0.622, 95% CI 0.539-0.717), ventricular arrhythmias (HR 0.637, 95% CI 0.441-0.919), malignant arrhythmias (HR 0.656, 95% CI 0.571-0.754), new-onset AF (HR 0.672, 95% CI 0.517-0.875), and myocardial infarction (HR 0.818, 95% CI 0.687-0.974), with no significant differences in the remaining outcomes. Differences were greater when TTS was compared with heart failure with reduced ejection fraction. CONCLUSIONS: TTS is associated with lower risk of adverse events than HF. Further research is needed on mental health in its pathogenesis and prognosis.
No takes yet. Share an insight, caveat, or question.
Tartaglia et al. (2026) conducted an observational in Takotsubo syndrome and heart failure (n=267,804). Takotsubo syndrome vs. Heart failure was evaluated on 3-year risk of all-cause death, major adverse cardiovascular events (MACE; myocardial infarction or ischaemic stroke), and acute HF (HR 0.622, 95% CI 0.539-0.717). Takotsubo syndrome was associated with a lower risk of acute heart failure compared to heart failure (HR 0.622; 95% CI 0.539-0.717), with no significant differences in all-cause death or MACE.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: